Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US9464088B2 · kind B2 · utility
49Cited by
79References
49Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 28, 2014 |
| Grant date | Oct 11, 2016 |
| Priority date | — |
| Expiry date | May 28, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides piperidin-4-yl azetidine derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase 1 (JAK1) and are useful in the treatment of diseases related to the activity of JAK1 including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.